Immortagen, Inc. Completes Series A Financing for Personalized Medicine

Coralville, USA, September 19, 2016 (Newswire.com) - ​Immortagen, Inc. announced today that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen's product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required.  Founded by a team of leading physician-researchers and complemented with proven management , Immortagen believes it will fill a key gap in the global oncology market.

Source: Immortagen, Inc.